» Articles » PMID: 25535951

Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology

Overview
Journal PLoS One
Date 2014 Dec 24
PMID 25535951
Citations 268
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The recently developed histological scoring system for non-alcoholic fatty liver disease (NAFLD) by the NASH Clinical Research Network (NASH-CRN) has been widely used in clinical settings, but is increasingly employed in preclinical research as well. However, it has not been systematically analyzed whether the human scoring system can directly be converted to preclinical rodent models. To analyze this, we systematically compared human NAFLD liver pathology, using human liver biopsies, with liver pathology of several NAFLD mouse models. Based upon the features pertaining to mouse NAFLD, we aimed at establishing a modified generic scoring system that is applicable to broad spectrum of rodent models.

Methods: The histopathology of NAFLD was analyzed in several different mouse models of NAFLD to define generic criteria for histological assessment (preclinical scoring system). For validation of this scoring system, 36 slides of mouse livers, covering the whole spectrum of NAFLD, were blindly analyzed by ten observers. Additionally, the livers were blindly scored by one observer during two separate assessments longer than 3 months apart.

Results: The criteria macrovesicular steatosis, microvesicular steatosis, hepatocellular hypertrophy, inflammation and fibrosis were generally applicable to rodent NAFLD. The inter-observer reproducibility (evaluated using the Intraclass Correlation Coefficient) between the ten observers was high for the analysis of macrovesicular steatosis and microvesicular steatosis (ICC = 0.784 and 0.776, all p<0.001, respectively) and moderate for the analysis of hypertrophy and inflammation (ICC = 0.685 and 0.650, all p<0.001, respectively). The intra-observer reproducibility between the different observations of one observer was high for the analysis of macrovesicular steatosis, microvesicular steatosis and hypertrophy (ICC = 0.871, 0.871 and 0.896, all p<0.001, respectively) and very high for the analysis of inflammation (ICC = 0.931, p<0.001).

Conclusions: We established a simple NAFLD scoring system with high reproducibility that is applicable for different rodent models and for all stages of NAFLD etiology.

Citing Articles

Hepatic Deletion of Carbohydrate Response Element Binding Protein Impairs Hepatocarcinogenesis in a High-Fat Diet-Induced Mouse Model.

Karim M, Prey J, Willer F, Leiner H, Yasser M, Dombrowski F Int J Mol Sci. 2025; 26(5).

PMID: 40076869 PMC: 11900174. DOI: 10.3390/ijms26052246.


improves host metabolism in diet-induced obesity.

Huang W, Zhu W, Lin Y, Chan F, Xu Z, Ng S Gut Microbes. 2025; 17(1):2467193.

PMID: 39976263 PMC: 11845086. DOI: 10.1080/19490976.2025.2467193.


Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis.

Canova N, Sipkova J, Arora M, Pavlikova Z, Kucera T, Seda O Front Pharmacol. 2025; 16:1476994.

PMID: 39968178 PMC: 11832397. DOI: 10.3389/fphar.2025.1476994.


Mucus-penetrating microbiota drive chronic low-grade intestinal inflammation and metabolic dysregulation.

Kordahi M, Daniel N, Gewirtz A, Chassaing B Gut Microbes. 2025; 17(1):2455790.

PMID: 39865067 PMC: 11776472. DOI: 10.1080/19490976.2025.2455790.


Folic Acid and Methyltetrahydrofolate Supplementation in the Mouse Model with Hepatic Steatosis.

Christensen K, Faquette M, Leclerc D, Keser V, Luan Y, Bennett-Firmin J Nutrients. 2025; 17(1.

PMID: 39796516 PMC: 11723006. DOI: 10.3390/nu17010082.


References
1.
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

2.
van den Hoek A, van der Hoorn J, Maas A, van den Hoogen R, van Nieuwkoop A, Droog S . APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes Obes Metab. 2013; 16(6):537-44. DOI: 10.1111/dom.12252. View

3.
Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C . Hepatocellular ballooning in NASH. J Hepatol. 2010; 53(4):719-23. PMC: 2930100. DOI: 10.1016/j.jhep.2010.04.031. View

4.
Merriman R, Ferrell L, Patti M, Weston S, Pabst M, Aouizerat B . Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006; 44(4):874-80. DOI: 10.1002/hep.21346. View

5.
Westerterp M, van der Hoogt C, de Haan W, Offerman E, Dallinga-Thie G, Jukema J . Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006; 26(11):2552-9. DOI: 10.1161/01.ATV.0000243925.65265.3c. View